Phentermine and Topiramate
Active ingredient: Phentermine Hydrochloride, Topiramate
In short: Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overwe
What is Phentermine and Topiramate used for?
Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:
Adults and pediatric patients aged 12 years and older with obesity
Adults with overweight in the presence of at least one weight-related comorbid condition
Limitations of Use
The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established.
The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
Phentermine and Topiramate dosage
Prior to phentermine and topiramate extended-release capsule initiation and during treatment with phentermine and topiramate extended-release capsules, the following is recommended:
Obtain a negative pregnancy test before initiating phentermine and topiramate extended-release capsules in patients who can become pregnant and monthly during phentermine and topiramate extended-release capsule therapy. Phentermine and topiramate extended-release capsules are contraindicated during pregnancy [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.3)].
Obtain a blood chemistry profile that includes bicarbonate, creatinine, and potassium in all patients, and glucose in patients with type 2 diabetes mellitus on antidiabetic medication prior to initiating phentermine and topiramate extended-release capsule treatment and periodically during treatment .
The recommended dosage, titration, and administration of phentermine and topiramate extended-release capsules are as follows:
Take phentermine and topiramate extended-release capsules orally once daily in the morning with or without food. Avoid administration of phentermine and topiramate extended-release capsules in the evening due to the possibility of insomnia.
The recommended starting dosage of phentermine and topiramate extended-release capsules is one capsule (containing 3.75 mg of phentermine and 23 mg of topiramate) (3.75 mg/23 mg) taken orally once daily for 14 days; after 14 days increase to the recommended dosage of phentermine and topiramate extended-release capsules 7.5 mg/46 mg orally once daily.
After 12 weeks of treatment with phentermine and topiramate extended-release capsules 7.5 mg/46 mg, evaluate weight loss for adults or BMI reduction for pediatric patients aged 12 years and older. If an adult patient has not lost at least 3% of baseline body weight or a pediatric patient has not experienced a reduction of at least 3% of baseline BMI, increase the dosage to phentermine and topiramate extended-release capsules 11.25 mg/69 mg orally once daily for 14 days; followed by an increase in the dosage to phentermine and topiramate extended-release capsules 15 mg/92 mg orally once daily.
After 12 weeks of treatment with phentermine and topiramate extended-release capsules 15 mg/92 mg, evaluate weight loss for adults or BMI reduction for pediatric patients aged 12 years and older. If an adult patient has not lost at least 5% of baseline body weight or a pediatric patient has not experienced a reduction of at least 5% of baseline BMI, discontinue phentermine and topiramate extended-release capsules , as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment. …
How to take Phentermine and Topiramate — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Embryo-Fetal Toxicity
Inform patients who can become pregnant that phentermine and topiramate extended-release capsules can cause fetal harm and patients should avoid getting pregnant while taking phentermine and topiramate extended-release capsules [see Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.3)].
Advise patients who can become pregnant:
that pregnancy testing is recommended before initiating phentermine and topiramate extended-release capsules and monthly during therapy;
to use effective contraception during phentermine and topiramate extended-release capsule therapy;
who experience spotting while taking a combined oral contraceptive to notify their health care provider;
with a known or suspected pregnancy to stop phentermine and topiramate extended-release capsules immediately and notify their health care provider. …
Warnings & precautions
Do not take this medicine if: Phentermine and topiramate extended-release capsules are contraindicated in patients:
Who are pregnant
With glaucoma
With hyperthyroidism
Taking or within 14 days of stopping a monoamine oxidase inhibitors
With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release capsules, or idiosyncrasy to the sympathomimetic amines. Anaphylaxis and angioedema have occurred with topiramate .
Phentermine and topiramate extended-release capsules can cause fetal harm. Data from pregnancy registries and epidemiologic studies indicate that a fetus exposed to topiramate in the first trimester of pregnancy has an increased risk of major congenital malformations, including but not limited to cleft lip and/or cleft palate (oral clefts), and of being small for gestational age (SGA). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural malformations, including craniofacial defects, and reduced fetal weights occurred in offspring. A negative pregnancy test is recommended before initiating phentermine and topiramate extended-release capsule treatment in patients who can become pregnant and monthly during phentermine and topiramate extended-release capsule therapy. Advise patients who can become pregnant of the potential risk to a fetus and to use effective contraception during phentermine and topiramate extended-release capsule therapy .
Phentermine and Topiramate Extended-Release Capsules Risk Evaluation and Mitigation Strategy (REMS)
Because of the teratogenic risk associated with phentermine and topiramate extended-release capsule therapy, phentermine and topiramate extended-release capsules are available through a limited program under the REMS. …
Phentermine and Topiramate side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Embryo-Fetal Toxicity
Suicidal Behavior and Ideation
Risk of Ophthalmologic Adverse Reactions
Mood and Sleep Disorders
Cognitive Impairment
Slowing of Linear Growth
Metabolic Acidosis
Decrease in Renal Function
Risk of Seizures with Abrupt Withdrawal of Phentermine and Topiramate Extended-Release Capsules
Kidney Stones
Oligohidrosis and Hyperthermia
Hypokalemia
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions
Serious Skin Reactions
Anaphylaxis and Angioedema
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
The data described herein reflect exposure to phentermine and topiramate extended-release capsules in two 1-year, randomized, double-blind, placebo-controlled, multicenter clinical trials and two supportive trials in 2,318 adult patients with overweight or obesity [936 (40%) patients with hypertension, 309 (13%) patients with type 2 diabetes mellitus, 808 (35%) patients with BMI greater than 40 kg/m2] exposed for a mean duration of 298 days. …
Drug interactions
Table 5 displays clinically significant drug interactions with phentermine and topiramate extended-release capsules.
Monoamine Oxidase Inhibitors
Clinical Impact | Concomitant use of phentermine with monoamine oxidase inhibitors (MAOIs) increases the risk of hypertensive crisis.
Intervention | Concomitant use of phentermine and topiramate extended-release capsules is contraindicated during MAOI treatment and within 14 days of stopping an MAOI.
Oral Contraceptives
Clinical Impact | Coadministration of multiple-dose phentermine and topiramate extended-release capsules 15 mg/92 mg once daily with a single dose of oral contraceptive containing 35 mcg ethinyl estradiol (estrogen component) and 1 mg norethindrone (progestin component), in obese otherwise healthy volunteers, decreased the exposure of ethinyl estradiol by 16% and increased the exposure of norethindrone by 22% . Although this interaction is not anticipated to increase the risk of pregnancy, irregular bleeding (spotting) may occur more frequently due to both the increased exposure to the progestin and lower exposure to the estrogen, which tends to stabilize the endometrium. …
About this medicine
Phentermine and topiramate extended-release capsules are comprised of immediate-release phentermine hydrochloride (expressed as the weight of the free base) and extended-release topiramate. Phentermine and topiramate extended-release capsules contain phentermine hydrochloride USP, a sympathomimetic amine anorectic, and topiramate USP, a sulfamate-substituted monosaccharide.
Phentermine Hydrochloride, USP
The chemical name of phentermine hydrochloride, USP is α,α-dimethylphenethylamine hydrochloride. The molecular formula is C10H15N • HCl and its molecular weight is 185.7 (hydrochloride salt) or 149.2 (free base). Phentermine hydrochloride, USP is a white, odorless, hygroscopic, crystalline powder that is soluble in water, methanol, and ethanol. Its structural formula is:
Topiramate, USP
Topiramate, USP is 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate. The molecular formula is C12H21NO8S and its molecular weight is 339.4. Topiramate, USP is a white to off-white crystalline powder with a bitter taste. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 918df93d-e033-4419-adcc-e21655ef8158. Read the full official label on DailyMed.
Related medicines
Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Orlistat Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine